产品
编 号：F058114
分子式：C19H21FN4O3S
分子量：404.46
分子式：C19H21FN4O3S
分子量：404.46
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1181083-81-7
产品详情
生物活性：
CLP290 is an orally available activator of the neuron-specific K+-Cl? cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ rats.
体内研究：
CLP290 (oral gavage; 100 mg/kg; twice a day; 7 day) enhances KCC2 activity and restores Cl-?transport in superficial dorsal horn (SDH)neurons of morphine-treated rats, and prevents morphine-induced hyperalgesia (MIH) in rat.Animal Model:Adult male rats (300?g, >postnatal day 60)
Dosage:100 mg/kg
Administration:Oral gavage; 100 mg/kg; twice a day; 7day
Result:Rescued established MIH and prevented its development by restoring Cl-?transport or preventing its deficiency in the SDH.
CLP290 is an orally available activator of the neuron-specific K+-Cl? cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ rats.
体内研究：
CLP290 (oral gavage; 100 mg/kg; twice a day; 7 day) enhances KCC2 activity and restores Cl-?transport in superficial dorsal horn (SDH)neurons of morphine-treated rats, and prevents morphine-induced hyperalgesia (MIH) in rat.Animal Model:Adult male rats (300?g, >postnatal day 60)
Dosage:100 mg/kg
Administration:Oral gavage; 100 mg/kg; twice a day; 7day
Result:Rescued established MIH and prevented its development by restoring Cl-?transport or preventing its deficiency in the SDH.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备